Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolizationKoichiro Yamakado, Masato Yamaguchi, Shiro Miyayama et al.|Japanese Journal of Radiology|2014Cited by 98
Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?Koichiro Yamakado, Masato Yamaguchi, Shiro Miyayama et al.|Japanese Journal of Radiology|2012Cited by 77
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Masatoshi Kudo, Yasunori Kawaguchi et al.|Investigational New Drugs|2018Cited by 49
Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B)Koichiro Yamakado, Masato Yamaguchi, Shiro Miyayama et al.|Japanese Journal of Radiology|2014Cited by 44
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)Hisashi Hidaka, Yasuaki Arai, Namiki Izumi et al.|Medical Oncology|2019Cited by 23